DatStat, an R1 company joined R1 RCM in April 2020, with a focus on providing innovative technology to support health researchers and patient-centered organizations in conducting breakthrough research. The enterprise-level Data Collection Platform offers automation for complex longitudinal studies, clinical trials, and patient registries, along with mobile-friendly surveys and tailored feedback to drive deeper participant engagement, higher recruitment, survey completion rates, and long-term retention.
Combined with expert services, DatStat's software has facilitated research at renowned institutions including the COPD Foundation, Group Health Cooperative, Seattle Children’s Hospital, Ontario HIV Treatment Network, and many others. Founded in 1997, DatStat operates in the Health Care industry, with its headquarters located in the United States.
After being acquired by R1 RCM, DatStat continues its mission to contribute to a healthier world through technology-driven solutions for the healthcare and research sectors. Despite the absence of specific details regarding the last investment or investors, DatStat's extensive track record and alignment with R1 RCM present promising opportunities for further growth and impact.
There is no investment information
No recent news or press coverage available for DatStat, an R1 company.